DDInter1667 DDInter1376
Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by the FDA in October 2008 and it is also approved in Europe and Canada. Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have a negative impact on the quality of life of patients
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Silodosin {u} (Compound) resembles {v} (Compound) Tamsulosin
Silodosin {u} (Compound) binds {v} (Gene) CYP3A4
Silodosin {u} (Compound) causes {v} (Side Effect) Dizziness
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Silodosin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Silodosin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Silodosin (Compound) resembles Tamsulosin (Compound)
Silodosin (Compound) binds CYP3A4 (Gene)
Silodosin (Compound) causes Dizziness (Side Effect)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Silodosin may lead to a major life threatening interaction when taken with Cobicistat
Silodosin may lead to a major life threatening interaction when taken with Clarithromycin